Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment
The content for this activity is based on the satellite symposium Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment that was presented on October 24, 2016 in Los Angeles, CA. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with IPF.
Upon completion of this activity, participants will be better able to do the following:
- Implement multidisciplinary clinical and imaging approaches to achieve more timely and accurate diagnosis of IPF
- Develop IPF treatment strategies based on key guideline recommendations and examine the supporting clinical trial data
- Describe key elements of an individualized approach to IPF treatment that involves shared decision-making
Fernando J. Martinez, MD, MS (Program Chair)
Kevin R. Flaherty, MD, MS
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Fernando J. Martinez, MD, MS
Consultant/Advisor: Adept Pharma & Bioscience; AstraZeneca; Boehringer Ingelheim GmbH; Clarion Healthcare; Concert Pharmaceuticals, Inc.; Genentech, Inc.; GSK group of companies; Integritas; Unity/Medical Leverage; Mereo BioPharma Group plc; Novartis AG; ProterixBio, Inc.; Theravance Biopharma
Research Grant: Afferent Pharmaceuticals; AstraZeneca; Bayer AG; Boehringer Ingelheim GmbH; Biogen; Gilead; GSK group of companies; Veracyte, Inc.
Speakers’ Bureau: AstraZeneca; Boehringer Ingelheim GmbH; Novartis AG; WebMD LLC.
Royalties/Patents: UpToDate, Inc.
Kevin R. Flaherty, MD, MS
Consultant/Advisor: Aeolus Pharmaceuticals; Boehringer Ingelheim GmbH; FibroGen, Inc.; Genentech, Inc.; ImmuneWorks; PharmAkea Therapeutics; The Degge Group Ltd.; Veracyte, Inc.
Research Grant: Afferent Pharmaceuticals; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Genentech, Inc.
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
This CME activity has been peer-reviewed by CHEST® Journal.
This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; and Boehringer Ingelheim Pharmaceuticals, Inc, do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.25 AMA PRA Category 1 Credit(s)™
- 1.25 Non-physician